Glecaprevir/Pibrentasvir

DRUG19 trials

Sponsors

Nakamura Masato, Kirby Institute, AbbVie, Tongji Hospital, University of Maryland, Baltimore

Conditions

Chronic Hepatitis CChronic Hepatitis cChronic hepatitis C infection Anti-viral therapyDigestive System DiseasesESRDEnd Stage Renal DiseaseHCVHCV Infection

Early Phase 1

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

CompletedNCT04682509

NYU Langone HealthESRD

Start: 2022-03-20End: 2024-02-28Updated: 2024-06-25

Phase 1

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Not yet recruitingNCT07040319

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C

Start: 2026-02-28End: 2027-07-30Target: 30Updated: 2026-01-29

Phase 2

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

RecruitingNCT05637879

White River Junction Veterans Affairs Medical CenterPTSD

Start: 2023-12-18End: 2026-09-30Target: 92Updated: 2025-04-24

Phase 3

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

CompletedNCT02634008

Kirby InstituteHepatitis C, Acute

Start: 2016-06-30End: 2021-04-30Updated: 2022-08-22

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

CompletedNCT02692703

AbbVieChronic Hepatitis C, HCV, Hepatitis C Virus

Start: 2016-04-22End: 2017-06-29Updated: 2021-07-13

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

CompletedNCT02939989

AbbVieHepatitis C Virus Infection

Start: 2016-11-21End: 2021-07-30Updated: 2022-05-04

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

CompletedNCT02966795

AbbVieHepatitis C Virus (HCV)

Start: 2017-01-25End: 2018-08-29Updated: 2021-07-30

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

CompletedNCT03069365

AbbVieHepatitis C Virus (HCV)

Start: 2017-03-28End: 2018-06-05Updated: 2019-03-04

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

CompletedNCT03089944

AbbVieHepatitis C Virus (HCV)

Start: 2017-04-28End: 2019-11-08Updated: 2020-07-13

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

CompletedNCT03212521

AbbVieHepatitis C Virus (HCV)

Start: 2017-08-07End: 2018-08-13Updated: 2019-09-04

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

CompletedNCT03219216

AbbVieHepatitis C Virus (HCV)

Start: 2018-06-06End: 2019-03-11Updated: 2020-03-17

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

CompletedNCT03222583

AbbVieHepatitis C Virus (HCV)

Start: 2017-10-04End: 2019-02-15Updated: 2019-12-23

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

CompletedNCT03235349

AbbVieHepatitis C Virus (HCV)

Start: 2017-09-29End: 2019-02-25Updated: 2019-11-21

Phase 4

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

WithdrawnNCT04235049

University of Maryland, BaltimoreHCV Infection

Start: 2021-10-01End: 2024-10-30Updated: 2021-05-06

Active, not recruitingJPRN-jRCTs031200042

Nakamura MasatoChronic hepatitis C infection Anti-viral therapy

Start: 2021-01-21Target: 44Updated: 2025-07-18

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

CompletedNCT04575896

Johns Hopkins UniversityEnd Stage Renal Disease, Hepatitis C

Start: 2020-11-20End: 2023-12-01Updated: 2024-01-10

Unknown Phase

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

CompletedNCT03492112

Kirby InstituteHepatitis C

Start: 2019-09-10End: 2021-11-30Updated: 2023-01-17

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

Kirby InstituteDigestive System Diseases, Hepatitis, Hepatitis C +3

Start: 2019-05-28End: 2022-08-31Target: 600Updated: 2022-04-14

Glecaprevir/Pibrentasvir Real-world Study in China

Tongji HospitalChronic Hepatitis c

Start: 2019-06-30End: 2022-06-30Target: 800Updated: 2019-05-08

Related Papers

A point-of-care testing intervention to improve hepatitis C diagnosis and treatment uptake among people attending Aboriginal community controlled health services: the SCALE-C study.

2025-11-17

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.

2023-07-276 citations

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

Infectious Diseases and Therapy2022-02-173 citations

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.

2020-09-177 citations

Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).

2020-07-1640 citations

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Liver International2019-12-1062 citations

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.

2019-11-02103 citations

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

2019-10-239 citations

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.

2018-11-0241 citations

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Hepatology2018-04-19176 citations